{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:46:05Z","timestamp":1790239565016,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Stromal-derived intratumoural heterogeneity (ITH) has been shown to undermine molecular stratification of patients into appropriate prognostic\/predictive subgroups. Here, using several clinically relevant colorectal cancer (CRC) gene expression signatures, we assessed the susceptibility of these signatures to the confounding effects of ITH using gene expression microarray data obtained from multiple tumour regions of a cohort of 24 patients, including central tumour, the tumour invasive front and lymph node metastasis. Sample clustering alongside correlative assessment revealed variation in the ability of each signature to cluster samples according to patient-of-origin rather than region-of-origin within the multi-region dataset. Signatures focused on cancer-cell intrinsic gene expression were found to produce more clinically useful, patient-centred classifiers, as exemplified by the CRC intrinsic signature (CRIS), which robustly clustered samples by patient-of-origin rather than region-of-origin. These findings highlight the potential of cancer-cell intrinsic signatures to reliably stratify CRC patients by minimising the confounding effects of stromal-derived ITH.<\/jats:p>","DOI":"10.1038\/ncomms15657","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T12:17:05Z","timestamp":1496233025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9160-283X","authenticated-orcid":false,"given":"Philip D.","family":"Dunne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Alderdice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aideen C.","family":"Roddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M. B.","family":"McCorry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S.","family":"McDade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick G.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Longley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darragh G.","family":"McArt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,31]]},"reference":[{"key":"BFncomms15657_CR1","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869\u201310874 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms15657_CR2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747\u2013752 (2000).","journal-title":"Nature"},{"key":"BFncomms15657_CR3","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1158\/0008-5472.CAN-12-3232","volume":"72","author":"SE Kern","year":"2012","unstructured":"Kern, S. E. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res. 72, 6097\u20136101 (2012).","journal-title":"Cancer Res."},{"key":"BFncomms15657_CR4","doi-asserted-by":"crossref","first-page":"e48877","DOI":"10.1371\/journal.pone.0048877","volume":"7","author":"R Sanz-Pamplona","year":"2012","unstructured":"Sanz-Pamplona, R. et al. Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. PLoS ONE 7, e48877 (2012).","journal-title":"PLoS ONE"},{"key":"BFncomms15657_CR5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature12625","volume":"501","author":"RA Burrell","year":"2013","unstructured":"Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501, 338\u2013345 (2013).","journal-title":"Nature"},{"key":"BFncomms15657_CR6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.tig.2008.10.012","volume":"25","author":"K Polyak","year":"2009","unstructured":"Polyak, K., Haviv, I. & Campbell, I. G. Co-evolution of tumor cells and their microenvironment. Trends Genet. 25, 30\u201338 (2009).","journal-title":"Trends Genet."},{"key":"BFncomms15657_CR7","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350\u20131356 (2015).","journal-title":"Nat. Med."},{"key":"BFncomms15657_CR8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng.3224","volume":"47","author":"C Isella","year":"2015","unstructured":"Isella, C. et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 47, 312\u2013319 (2015).","journal-title":"Nat. Genet."},{"key":"BFncomms15657_CR9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/ng.3225","volume":"47","author":"A Calon","year":"2015","unstructured":"Calon, A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47, 320\u2013329 (2015).","journal-title":"Nat. Genet."},{"key":"BFncomms15657_CR10","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-0032","volume":"22","author":"PD Dunne","year":"2016","unstructured":"Dunne, P. D. et al. Challenging the cancer molecular stratification dogma: intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer. Clin. Cancer Res. 22, 4095\u20134104 (2016).","journal-title":"Clin. Cancer Res."},{"key":"BFncomms15657_CR11","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.1158\/1078-0432.CCR-09-1431","volume":"15","author":"RN Jorissen","year":"2009","unstructured":"Jorissen, R. N. et al. Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer. Clin. Cancer Res. 15, 7642\u20137651 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFncomms15657_CR12","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1200\/JCO.2005.00.695","volume":"23","author":"S Eschrich","year":"2005","unstructured":"Eschrich, S. et al. Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol. 23, 3526\u20133535 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFncomms15657_CR13","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2011.35.4498","volume":"29","author":"RD Kennedy","year":"2011","unstructured":"Kennedy, R. D. et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J. Clin. Oncol. 29, 4620\u20134626 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFncomms15657_CR14","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2011.39.5814","volume":"30","author":"V Popovici","year":"2012","unstructured":"Popovici, V. et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J. Clin. Oncol. 30, 1288\u20131295 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFncomms15657_CR15","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.2008.21.6663","volume":"27","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem, E. et al. Randomized phase III trial comparing biweekly infusional fluorouracil\/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27, 3117\u20133125 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFncomms15657_CR16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ccr.2012.08.013","volume":"22","author":"A Calon","year":"2012","unstructured":"Calon, A. et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 22, 571\u2013584 (2012).","journal-title":"Cancer Cell"},{"key":"BFncomms15657_CR17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1158\/1538-7445.AM2016-107","volume":"76","author":"A Bertotti","year":"2016","unstructured":"Bertotti, A. et al. Abstract 107: unsupervised analysis of cancer-cell intrinsic transcriptional traits defines a new classification system for colorectal cancer with improved predictive and prognostic value. Cancer Res. 76, 107\u2013107 (2016).","journal-title":"Cancer Res."},{"key":"BFncomms15657_CR18","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-16-1044","volume":"22","author":"JS Morris","year":"2016","unstructured":"Morris, J. S. & Kopetz, S. Tumor microenvironment in gene signatures: critical biology or confounding noise? Clin. Cancer Res. 22, 3989\u20133991 (2016).","journal-title":"Clin. Cancer Res."},{"key":"BFncomms15657_CR19","doi-asserted-by":"crossref","unstructured":"Dienstmann, R. et al. Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes. ASCO Meeting Abstracts. J. Clin. Oncol. 32, abstract 3511 (2014).","DOI":"10.1200\/jco.2014.32.15_suppl.3511"},{"key":"BFncomms15657_CR20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nm.3175","volume":"19","author":"A Sadanandam","year":"2013","unstructured":"Sadanandam, A. et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19, 619\u2013625 (2013).","journal-title":"Nat. Med."},{"key":"BFncomms15657_CR21","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330\u2013337 (2012).","DOI":"10.1038\/nature11252"},{"key":"BFncomms15657_CR22","doi-asserted-by":"crossref","first-page":"e1001453","DOI":"10.1371\/journal.pmed.1001453","volume":"10","author":"L Marisa","year":"2013","unstructured":"Marisa, L. et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 10, e1001453 (2013).","journal-title":"PLoS Med."},{"key":"BFncomms15657_CR23","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nm.3174","volume":"19","author":"F De Sousa E Melo","year":"2013","unstructured":"De Sousa E Melo, F. et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 19, 614\u2013618 (2013).","journal-title":"Nat. Med."},{"key":"BFncomms15657_CR24","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(87)90552-6","volume":"1","author":"JR Jass","year":"1987","unstructured":"Jass, J. R., Love, S. B. & Northover, J. M. A new prognostic classification of rectal cancer. Lancet 1, 1303\u20131306 (1987).","journal-title":"Lancet"},{"key":"BFncomms15657_CR25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2559.2006.02549.x","volume":"50","author":"JR Jass","year":"2007","unstructured":"Jass, J. R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50, 113\u2013130 (2007).","journal-title":"Histopathology"},{"key":"BFncomms15657_CR26","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/jcp.40.9.1016","volume":"40","author":"JR Jass","year":"1987","unstructured":"Jass, J. R. & Morson, B. C. Reporting colorectal cancer. J. Clin. Pathol. 40, 1016\u20131023 (1987).","journal-title":"J. Clin. Pathol."},{"key":"BFncomms15657_CR27","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/gutjnl-2011-300843","volume":"61","author":"RF Logan","year":"2012","unstructured":"Logan, R. F. et al. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut 61, 1439\u20131446 (2012).","journal-title":"Gut"},{"key":"BFncomms15657_CR28","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/j.gastro.2016.08.001","volume":"151","author":"A Martinez-Cardus","year":"2016","unstructured":"Martinez-Cardus, A. et al. Epigenetic homogeneity within colorectal tumors predicts shorter relapse-free and overall survival times for patients with locoregional cancer. Gastroenterology 151, 961\u2013972 (2016).","journal-title":"Gastroenterology"},{"key":"BFncomms15657_CR29","doi-asserted-by":"crossref","first-page":"e15543","DOI":"10.1371\/journal.pone.0015543","volume":"5","author":"Y Hoshida","year":"2010","unstructured":"Hoshida, Y. Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS ONE 5, e15543 (2010).","journal-title":"PLoS ONE"},{"key":"BFncomms15657_CR30","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1200\/JCO.2015.65.4699","volume":"34","author":"D Niedzwiecki","year":"2016","unstructured":"Niedzwiecki, D. et al. Association between results of a gene expression signature assay and recurrence-free interval in patients with stage II colon cancer in cancer and leukemia group B 9581 (alliance). J. Clin. Oncol. 34, 3047\u20133053 (2016).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms15657.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms15657","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncomms15657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms15657.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:43:31Z","timestamp":1671756211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms15657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,31]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,8,11]]}},"alternative-id":["BFncomms15657"],"URL":"https:\/\/doi.org\/10.1038\/ncomms15657","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,31]]},"assertion":[{"value":"7 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.G.J.: Previous Founder and Shareholder of Almac Diagnostics; CV6 Therapeutics: Expert Advisor and Shareholder; Chugai Pharmaceuticals: Consultant. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15657"}}